investor.acceleronpharma.com

Acceleron Pharma » Investors

Aug 14, 2015 at 4:00 PM ET. Intraday data provided by eSignal. At Acceleron, we aim to transform the lives of people suffering from cancer and orphan diseases by discovering and developing innovative therapies. Acceleron scientists have world-leading expertise in developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily. Since our founding in 2004, Acceleron has brought multiple distinct, internally-discovered, developed and manufactured products. RECENT RELEASES View all.

http://investor.acceleronpharma.com/

OVERVIEW OF investor.acceleronpharma.com

TRAFFIC RANK

>1,000,000

REVIEWS

0

PAGES IN THIS WEBSITE

19

LINKS TO THIS WEBSITE

CONTACTS

ADDRESSES

SOCIAL LINKS

ONLINE SINCE

WEBSITE DETAILS

SEO

PAGES

SIMILAR SITES

TRAFFIC RANK FOR INVESTOR.ACCELERONPHARMA.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

October

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Wednesday

TRAFFIC BY CITY

Sign up

CUSTOMER REVIEWS

Average Rating: 2.7 out of 5 with 6 reviews

5 star

1

4 star

0

3 star

3

2 star

0

1 star

2

Hey there! Start your review of investor.acceleronpharma.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

LOAD TIME

2.2 seconds

FAVICON PREVIEW

16x16

CONTACTS AT INVESTOR.ACCELERONPHARMA.COM

ADD CONTACT

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

CONTENT

PAGES IN
THIS WEBSITE

19

SSL

EXTERNAL LINKS

19

SITE IP

206.200.251.19

LOAD TIME

2.236 sec

SCORE

6.2

PAGE TITLE

Acceleron Pharma » Investors | investor.acceleronpharma.com Reviews

<META> DESCRIPTION

Aug 14, 2015 at 4:00 PM ET. Intraday data provided by eSignal. At Acceleron, we aim to transform the lives of people suffering from cancer and orphan diseases by discovering and developing innovative therapies. Acceleron scientists have world-leading expertise in developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily. Since our founding in 2004, Acceleron has brought multiple distinct, internally-discovered, developed and manufactured products. RECENT RELEASES View all.

<META> KEYWORDS

1 acceleron

2 our company

3 management

4 board of directors

5 careers

6 partners

7 tgf β superfamily

8 sotatercept

9 luspatercept

10 dalantercept

CONTENT

Page content here

KEYWORDS ON PAGE

acceleron,our company,management,board of directors,careers,partners,tgf β superfamily,sotatercept,luspatercept,dalantercept,publications,investors and media,investors,press releases,in the news,events and presentations,sec filings,annual meeting,snapshot

SERVER

Microsoft-IIS/6.0

POWERED BY

ASP.NET

CONTENT-TYPE

utf-8

GOOGLE PREVIEW

Acceleron Pharma » Investors | investor.acceleronpharma.com Reviews

https://investor.acceleronpharma.com

Aug 14, 2015 at 4:00 PM ET. Intraday data provided by eSignal. At Acceleron, we aim to transform the lives of people suffering from cancer and orphan diseases by discovering and developing innovative therapies. Acceleron scientists have world-leading expertise in developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily. Since our founding in 2004, Acceleron has brought multiple distinct, internally-discovered, developed and manufactured products. RECENT RELEASES View all.

INTERNAL PAGES

investor.acceleronpharma.com

1

Acceleron Pharma » RSS News Feeds

http://investor.acceleronpharma.com/rss.cfm

POSTERS, PRESENTATIONS & PUBLICATIONS. Todd James, IRC. Senior Director, Investor Relations and Corporate Communications. Really Simple Syndication (RSS) is a format designed for sharing web content such as headlines. An RSS feed highlights fresh material for you, so you don't have to repeatedly check a site yourself for updates. How do I use RSS? Some web browsers, such as Firefox. Have RSS readers built in. There are also online aggregators, websites such as My Yahoo. Paste the URL into your reader.

2

Acceleron Pharma » Press Releases

http://investor.acceleronpharma.com/releases.cfm

POSTERS, PRESENTATIONS & PUBLICATIONS. Todd James, IRC. Senior Director, Investor Relations and Corporate Communications. Acceleron to Present at Credit Suisse Healthcare Conference Monday, November 7, 2016. Nov 2, 2016. Acceleron Pharma to Webcast Conference Call of Third Quarter 2016 Financial Results on November 3, 2016. Oct 27, 2016. Acceleron to Host Educational Webcast on Facioscapulohumeral Muscular Dystrophy (FSHD) with Leading Researcher and Provide Overview of ACE-083 Phase 2 Trial. Oct 13, 2016.

3

Acceleron Pharma to Host Second Quarter 2015 Financial Results Conference Call and Webcast on August 6, 2015 (NASDAQ:XLRN)

http://investor.acceleronpharma.com/releasedetail.cfm?ReleaseID=924406

Laquo; Previous Release. Next Release ». July 29, 2015. Acceleron Pharma to Host Second Quarter 2015 Financial Results Conference Call and Webcast on August 6, 2015. NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today announced that the Company will host a conference call and live webcast on. Thursday, August 6, 2015. View source version on businesswire.com.

4

Acceleron Pharma » Investors

http://investor.acceleronpharma.com/index.cfm

POSTERS, PRESENTATIONS & PUBLICATIONS. Todd James, IRC. Senior Director, Investor Relations and Corporate Communications. Acceleron Pharma Inc. (NASDAQ: XLRN). 4:00 PM ET on Nov 2, 2016. RECENT RELEASES View all. Nov 2, 2016. Acceleron to Present at Credit Suisse Healthcare Conference Monday, November 7, 2016. Oct 27, 2016. Acceleron Pharma to Webcast Conference Call of Third Quarter 2016 Financial Results on November 3, 2016. Oct 13, 2016. Sep 27, 2016. EVENTS and PRESENTATIONS View all. Nov 7, 2016.

5

Acceleron Pharma » Investor FAQs

http://investor.acceleronpharma.com/faq.cfm

POSTERS, PRESENTATIONS & PUBLICATIONS. Todd James, IRC. Senior Director, Investor Relations and Corporate Communications. Show all ». When was Acceleron Pharma founded? Acceleron was incorporated in the state of Delaware in June 2003 as Phoenix Pharma, Inc., and we subsequently changed our name to Acceleron Pharma Inc. and commenced operations in February 2004. Where is Acceleron Pharma's corporate headquarters? When does Acceleron's fiscal year end? Our fiscal year ends on December 31. Boston, MA 02116.

UPGRADE TO PREMIUM TO VIEW 14 MORE

TOTAL PAGES IN THIS WEBSITE

19

LINKS TO THIS WEBSITE

acceleronpharma.com

Acceleron Pharma » Our Company

http://www.acceleronpharma.com/our-company

POSTERS, PRESENTATIONS & PUBLICATIONS. ACE-083, A Locally-Acting Muscle Agent, Increases Muscle Volume In Healthy Volunteers. 14th International Congress on Neuromuscular Diseases. Luspatercept Decreases Transfusion Burden and Liver Iron Concentration in Regularly Transfused Adults with Beta-Thalassemia. 21st Congress . Luspatercept Increases Hemoglobin, Reduces Liver Iron Concentration and Improves Quality of Life in Non-Transfusion Dependent Adults with B.

acceleronpharma.com

Acceleron Pharma » Posters, Presentations & Publications

http://www.acceleronpharma.com/publications

POSTERS, PRESENTATIONS & PUBLICATIONS. Jul 8, 2016. ACE-083, A Locally-Acting Muscle Agent, Increases Muscle Volume In Healthy Volunteers. 14th International Congress on Neuromuscular Diseases; July 8, 2016. Jun 12, 2016. Luspatercept Decreases Transfusion Burden and Liver Iron Concentration in Regularly Transfused Adults with Beta-Thalassemia. 21st Congress of the European Hematology Association; June 9-12, 2016. Jun 11, 2016. Jun 10, 2016. Jun 10, 2016. Jun 10, 2016. Apr 2, 2016. ACE-083, a Locally-Act...

acceleronpharma.com

Acceleron Pharma » Careers

http://www.acceleronpharma.com/our-company/careers

POSTERS, PRESENTATIONS & PUBLICATIONS. Associate Director, Clinical Operations. Manager/Senior Manager, Clinical Quality Assurance. Research Associate, Bioanalytical Development. Scientist, Preclinical Pharmacology. Scientist, Protein Purification. Sr Research Associate, Protein Purification - Discovery. Acceleron Pharma is an equal opportunity employer. Acceleron Pharma only hires individuals that are legally authorized to work in the United States. Life Insurance (100% company paid), including dependen...

acceleronpharma.com

Acceleron Pharma » Pipeline

http://www.acceleronpharma.com/products

POSTERS, PRESENTATIONS & PUBLICATIONS. Acceleron is developing first-in-class therapies intended to transform patients’ lives. We focus on products with unique properties that can provide meaningful advantages over existing treatments, or that can address diseases for which no approved therapies exist. We have built a rich pipeline of biologic therapies and have four internally developed programs in clinical trials.

acceleronpharma.com

Acceleron Pharma » Dalantercept

http://www.acceleronpharma.com/products/dalantercept

POSTERS, PRESENTATIONS & PUBLICATIONS. The DART Study Part 1: Updated Results of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma. International Kidney Cancer Symposium. The DART Study Part 2: A Phase 2 Randomized, Double-Blind Study of Dalantercept plus Axitinib Compared to Placebo plus Axitinib in Patients. For Advanced / Metastatic Cancer. Dalantercept (ACE-041) is an investigational protein therapeutic that inhibits angiogenesis by preventing BMP9 and BMP10, proteins in the TGF-β superfami...

acceleronpharma.com

Acceleron Pharma » Sotatercept

http://www.acceleronpharma.com/products/sotatercept

POSTERS, PRESENTATIONS & PUBLICATIONS. Phase 1 Dose-Escalation Study of Sotatercept (ACE-011) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed and/or R. Safety and Hemoglobin Effect of Sotatercept, Administered Intravenously and Subcutaneously, for Maintenance of Hemoglobin in Hemodialysis Su. Average number of RBCs in normal adult circulation at any given time, accounting for roughly 25% of total body cell number. Sotatercept increases hemoglobin levels and RBCs by a novel me...

acceleronpharma.com

Acceleron Pharma » Management

http://www.acceleronpharma.com/our-company/management

POSTERS, PRESENTATIONS & PUBLICATIONS. John Knopf, Ph.D. Matthew L. Sherman, M.D. Ravi Kumar, Ph.D. John Quisel, J.D., Ph.D. SVP, Business Development and General Counsel. Christopher Rovaldi, M.Sc. SVP, Program Management and Operations. John Knopf, Ph.D. Matthew L. Sherman, M.D. Ravi Kumar, Ph.D. John Quisel, J.D., Ph.D. SVP, Business Development and General Counsel. Christopher Rovaldi, M.Sc. SVP, Program Management and Operations.

acceleronpharma.com

Acceleron Pharma » LUSPATERCEPT

http://www.acceleronpharma.com/products/luspatercept

POSTERS, PRESENTATIONS & PUBLICATIONS. Luspatercept Decreases Transfusion Burden and Liver Iron Concentration in Regularly Transfused Adults with Beta-Thalassemia. 21st Congress . Luspatercept Increases Hemoglobin, Reduces Liver Iron Concentration and Improves Quality of Life in Non-Transfusion Dependent Adults with B. For Rare Anemia Indications. Average number of RBCs in normal adult circulation at any given time, accounting for roughly 25% of total body cell number. For people with many of these rare ...

acceleronpharma.com

Acceleron Pharma » ACE-083

http://www.acceleronpharma.com/products/ace-083

POSTERS, PRESENTATIONS & PUBLICATIONS. ACE-083, A Locally-Acting Muscle Agent, Increases Muscle Volume In Healthy Volunteers. 14th International Congress on Neuromuscular Diseases. ACE-083, a Locally-Acting TGF-Beta Superfamily Ligand Trap, Increases Muscle Volume of Targeted Muscle: Preliminary Results from a Phase 1 D. Number of muscles in the human body. Number of distinct muscle diseases according to the Muscular Dystrophy Association (MDA). Types of muscle tissue: skeletal, smooth, and cardiac.

UPGRADE TO PREMIUM TO VIEW 10 MORE

TOTAL LINKS TO THIS WEBSITE

19

SOCIAL ENGAGEMENT

share.php

AcceleronPharma

OTHER SITES

investor.77nrg.com

Investor Relations | Seventy Seven Energy Inc. |

7/29/15 6:01 am CDT. Seventy Seven Energy Inc. Announces Second Quarter 2015 Operational and Financial Results. OKLAHOMA CITY- ( BUSINESS WIRE. There are no scheduled events at this time. Please check back later. Annual Reports and Proxy Statements.

investor.aam.com

Investor Overview | American Axle & Manufacturing

To move the world. American Axle and Manufacturing, Inc. at J.P. Morgan Auto Conference. 160;at 9:20 am ET. American Axle and Manufacturing, Inc. at J.P. Morgan Auto Conference. Wednesday, August 12, 2015 . 9:20 am ET . Click here for webcast. Click here to add this event to your calendar. Welcome to the American Axle and Manufacturing Holdings, Inc. (AAM) Investors' home page. AAM is a multi-billion dollar company with a footprint that has more than 30 facilities around the world. 160; 0.17. AAM Appoin...

investor.aarons.com

Investor Relations - Aaron's

Q2 2015 Aaron's Inc. Earnings Conference Call. 160;at 10:00 am ET. This has been a milestone year at Aaron’s. In April, Aaron’s completed the transformative acquisition of Progressive Finance resulting in the strategic positioning of the Company . April 15, 2014. Updated on April 16, 2014 to correct certain inadvertent errors in the original presentation. 160; 2.25. 08/14/15 4:03 pm ET. Minimum 20 minute delay. Aaron's, Inc. Announces Curt Doman Appointed to Board of Directors. 08/11/15 - 8:00 am.

investor.abiomed.com

Investor Relations | ABIOMED, Inc.

Skip to main navigation.

investor.abm.com

Investor Relations - ABM Industries Incorporated

Events & Presentations. Earnings & Financials. Events & Presentations. Earnings & Financials. 4:00 PM Mar 29, 2018. Delayed at least 20 minutes. Mar 7, 2018 at 8:30 AM ET. ABM Industries Q1 FY 2018 Conference Call. Feb 22, 2018. Barclays Industrial Select Conference. Jan 18, 2018 at 9:45 AM ET. ABM Industries Investor Day. Dec 14, 2017 at 8:30 AM ET. ABM Industries Q4 FY 2017 Conference Call. All events and presentations ». Mar 29, 2018. Mar 22, 2018. Mar 14, 2018. Mar 13, 2018. All press releases ».

investor.acceleronpharma.com

Acceleron Pharma » Investors

Aug 14, 2015 at 4:00 PM ET. Intraday data provided by eSignal. At Acceleron, we aim to transform the lives of people suffering from cancer and orphan diseases by discovering and developing innovative therapies. Acceleron scientists have world-leading expertise in developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily. Since our founding in 2004, Acceleron has brought multiple distinct, internally-discovered, developed and manufactured products. RECENT RELEASES View all.

investor.accenture.com

Accenture – Investor Relations

Skip to main content. Consumer Goods and Services. Click the menu icon to display the main navigation. Type anywhere at any time to use our smart search tool. Q2 2018 Earnings Announcement. View prior earnings releases, earnings call replays, transcripts and more. Accenture Technology Vision 2018. Leading In The New. View Our 2017 Letter to our Shareholders. Fiscal 2017 Annual Report and 10K. Accenture plc 2017 Proxy Statement. Search All SEC Filings. Q2 2018 Accenture Earnings Conference Call.

investor.accessitx.com

Cinedigm Digital Cinema Corp - Investor Relations

Acquisitions & Releasing. 4:00 PM ET on Aug 7, 2015. Pricing provided by eSignal. Hell and Back Again. Paradise Lost 3: Purgatory. Current and upcoming theatrical releases include Destin Daniel Cretton’s highly acclaimed. And Shaul Schwarz’s. Aug, 06, 2015. Cinedigm to Report First Quarter Fiscal 2016 Financial Results on Wednesday, August 12, 2015. Jul, 31, 2015. Cinedigm Appoints Four New Independent Directors. Jun, 29, 2015. Cinedigm Announces Fourth Quarter and Full Year Fiscal 2015 Financial Results.

investor.aceto.com

Aceto - Investor Relations Home

Aceto Fine Chem GmbH (Hamburg). Aceto France S.A.S. Aceto Health Ingredients GmbH (Hamburg). Aceto Pharma GmbH (Hamburg). Aceto Pharma (India) Private Ltd. Pharma Waldhof GmbH (Dusseldorf). Rising Pharmaceuticals, Inc. Aceto in the News. Finished Dosage Form Generics. Active Pharmaceutical Ingredients (API’s). ACETO to Present at the Jefferies 2015 Global Healthcare Conference. ACETO Reports Third Quarter Fiscal 2015 Results. ACETO Board of Directors Declares Quarterly Cash Dividend. Q3 2014 Aceto Earnin...

investor.aciworldwide.com

Investor Relations - ACI Worldwide, Inc.

Stock Quote and Chart. Stock Quote and Chart. ACI Worldwide, Inc. Third Quarter 2016 Financial Results. Nov 3, 2016 at 8:30 AM ET. ACI Worldwide, Inc. Reports Financial Results for the Quarter Ended September 30, 2016. File is in Briefcase. Quarterly Results Presentation (November 3, 2016). File is in Briefcase. ACI Worldwide Showcases Powerful New mCommerce Solutions at NRF 2017 to Meet the Challenges of Evolving Customer Shopping Habits. Jan 9, 2017. Jan 4, 2017. Nov 29, 2016. Jul 28, 2016 at 8:30 AM ET.

investor.aconex.com

Aconex

Return to aconex.com. South Australia Health and Medical Research Institute US$202.6M Value. Panama Canal Expansion US$3.2B Value. Denver RTD FasTracks and Capital Programs US$5B Value. Click here to view, download or print our IPO prospectus. Click here to view our Investor FAQ and find out more about Aconex. Sign up to Email Alerts. Click here to sign up for Aconex email alerts and announcements. Click here to see all of our videos. Keep up to date with all the latest news. Sign up for Email Alerts.